SCHEMBL486195

SCHEMBL486195

CC(O)C(O)N1CCCC1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.35
FDPS P14324 2/20 0.33
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835413 0.97 SMN1; SMN2 (0.38) SMN1; SMN2FDPSMEN1KMT2A
SCHEMBL20905549 0.82 SMN1; SMN2 (0.35) SMN1; SMN2FDPSMEN1KMT2A
SCHEMBL24264704 0.80 SMN1; SMN2 (0.38) SMN1; SMN2FDPSMEN1KMT2A
SCHEMBL20130470 0.79 DPP7 (0.33) SMN1; SMN2
SCHEMBL11156139 0.78 MC4R (0.39)
SCHEMBL18526726 0.78 SMN1; SMN2 (0.33) SMN1; SMN2FDPS
SCHEMBL24810232 0.77
SCHEMBL17377285 0.77 SMN1; SMN2 (0.35) SMN1; SMN2FDPSMEN1KMT2A
SCHEMBL9735269 0.76 SMN1; SMN2 (0.36) SMN1; SMN2MEN1KMT2A
SCHEMBL4359607 0.76 USP2 (0.39) SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106103396-A Compound, resin, lower layer film for lithography form material, lower layer film for lithography, pattern formation method and compound or the purification process of resin 三菱瓦斯化学株式会社 2016-11-09 CN disclosed
US-8912248-B2 Pigment dispersion and ink composition, curable composition and curable ink composition making use of the same FUJIFILM CORPORATION (JP) 2014-12-16 US disclosed
US-20140178462-A1 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS MARINA BIOTECH, INC. (US) 2014-06-26 US disclosed
CN-101477307-B Photomask blank, resist pattern forming process, and photomask preparation process SHIN ETSU EHEMICAL CO LTD 2012-12-12 CN disclosed
US-8293837-B2 Pigment dispersion, and ink composition, curable composition and curable ink composition produced with pigment dispersion FUJIFILM CORPORATION (JP) 2012-10-23 US disclosed
EP-2233536-B1 Pigment dispersion and ink composition, curable composition and curable ink composition making use of the same FUJIFILM CORP (JP) 2012-05-16 EP disclosed
EP-2233537-B1 Pigment dispersion, and ink composition, curable composition and curable ink composition produced with pigment dispersion FUJIFILM CORP (JP) 2012-02-01 EP disclosed
US-20100330154-A1 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS MARINA BIOTECH, INC. 2010-12-30 US disclosed
EP-2233537-A1 Pigment dispersion, and ink composition, curable composition and curable ink composition produced with pigment dispersion Fujifilm Corporation (JP) 2010-09-29 EP disclosed
EP-2233536-A1 Pigment dispersion and ink composition, curable composition and curable ink composition making use of the same Fujifilm Corporation (JP) 2010-09-29 EP disclosed
US-20100240825-A1 PIGMENT DISPERSION, AND INK COMPOSITION, CURABLE COMPOSITION AND CURABLE INK COMPOSITION PRODUCED WITH PIGMENT DISPERSION FUJIFILM CORPORATION (JP) 2010-09-23 US disclosed
US-20100240830-A1 PIGMENT DISPERSION AND INK COMPOSITION, CURABLE COMPOSITION AND CURABLE INK COMPOSITION MAKING USE OF THE SAME FUJIFILM CORPORATION (JP) 2010-09-23 US disclosed
EP-2211840-A2 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS novosom AG (DE) 2010-08-04 EP disclosed
CN-101477307-A Photomask blank, resist pattern forming process, and photomask preparation process SHINETSU CHEMICAL CO (JP) 2009-07-08 CN disclosed
WO-2009047006-A2 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS NOVOSOM AG (DE) 2009-04-16 WO disclosed
US-6548514-B1 Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders ASTRAZENECA AB (SE) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100330154-A1 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS LIPA, CETP, SGMS1 SMN1; SMN2 3859/4885FDPS 3438/4885MEN1 237/4885
US-20140178462-A1 AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS LIPA, CETP, SGMS1 SMN1; SMN2 3859/4885FDPS 3438/4885MEN1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.